| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/18/2002 | CA2425569A1 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer |
| 04/18/2002 | CA2425508A1 Targeted therapeutic agents |
| 04/18/2002 | CA2425356A1 Hedgehog antagonists, methods and uses related thereto |
| 04/18/2002 | CA2425298A1 Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof |
| 04/18/2002 | CA2425187A1 Detection of neurodegenerative disorders |
| 04/18/2002 | CA2425001A1 Novel serine protease genes related to dppiv |
| 04/18/2002 | CA2424823A1 Treatment of cancers by aplidine in conjunction with a myoprotector |
| 04/18/2002 | CA2424821A1 Gene encoding a human g-protein coupled receptor and its use |
| 04/18/2002 | CA2424317A1 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products |
| 04/18/2002 | CA2424299A1 Combination therapy for the treatment of estrogen-sensitive disease |
| 04/18/2002 | CA2424055A1 Medication delivery devices |
| 04/18/2002 | CA2422881A1 Human anti-epidermal growth factor receptor single-chain antibodies |
| 04/17/2002 | EP1197550A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| 04/17/2002 | EP1197496A1 Novel peptides |
| 04/17/2002 | EP1197228A1 Medicinal compositions for treating colorectal cancer |
| 04/17/2002 | EP1197227A1 Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method |
| 04/17/2002 | EP1197226A1 Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| 04/17/2002 | EP1197225A1 REMEDIES FOR DISEASES CAUSED BY PTH OR PTHrP |
| 04/17/2002 | EP1197224A1 Agents for ameliorating low vasopressin level |
| 04/17/2002 | EP1197223A1 Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy |
| 04/17/2002 | EP1197214A1 Medicinal compositions for preventing or treating diarrhea |
| 04/17/2002 | EP1197209A1 Percutaneously absorbable preparations |
| 04/17/2002 | EP1197143A1 Goodpasture's syndrome model mouse |
| 04/17/2002 | EP1196783A2 Screening for therapeutic agents being scap antagonists |
| 04/17/2002 | EP1196782A1 Catalytic anti-factor viii allo-antibodies |
| 04/17/2002 | EP1196635A2 Cell death related drug targets in yeast and fungi |
| 04/17/2002 | EP1196616A2 Replication-competent anti-cancer vectors |
| 04/17/2002 | EP1196598A1 Dsp-3 dual-specificity phosphatase |
| 04/17/2002 | EP1196577A2 Cell cycle and proliferation proteins |
| 04/17/2002 | EP1196575A2 Gtp-binding protein associated factors |
| 04/17/2002 | EP1196574A2 Human proteins involved in detoxification |
| 04/17/2002 | EP1196570A2 Human polypeptides and methods for the use thereof |
| 04/17/2002 | EP1196569A2 Electron transfer proteins |
| 04/17/2002 | EP1196568A1 Human lim domain proteins |
| 04/17/2002 | EP1196567A2 Human immune response molecules |
| 04/17/2002 | EP1196565A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 04/17/2002 | EP1196562A1 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 04/17/2002 | EP1196560A1 Neurotrophic factor receptor gfr-alpha-4 |
| 04/17/2002 | EP1196448A2 Homomeric and heteromeric ampa receptors |
| 04/17/2002 | EP1196432A2 FVIIa ANTAGONISTS |
| 04/17/2002 | EP1196414A1 Prodrugs of carbamate inhibitors of impdh |
| 04/17/2002 | EP1196411A1 Bradykinin b1 receptor antagonists |
| 04/17/2002 | EP1196409A2 Respiratory syncytial virus replication inhibitors |
| 04/17/2002 | EP1196400A1 Amino-alkyl derivatives |
| 04/17/2002 | EP1196395A1 Cyclized amino acid derivatives |
| 04/17/2002 | EP1196195A1 Nasogastric enteral formulations |
| 04/17/2002 | EP1196194A2 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS |
| 04/17/2002 | EP1196192A1 Method for enhancing an immune response |
| 04/17/2002 | EP1196191A1 Death domain containing receptor 5 |
| 04/17/2002 | EP1196189A2 Multiple agent diabetes therapy |
| 04/17/2002 | EP1196188A1 Vgf selective binding agents and methods of treating vgf-related disorders |
| 04/17/2002 | EP1196186A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 04/17/2002 | EP1196172A2 Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders |
| 04/17/2002 | EP1196171A2 Use of pyridoxin derivatives for the treatment of diabetes and related complications |
| 04/17/2002 | EP1196167A1 Method of reducing neuronal injury or apoptosis |
| 04/17/2002 | EP1196164A2 Methods and compositions for regulating gut motility and food intake |
| 04/17/2002 | EP1196163A2 Methods of treating and/or suppressing weight gain |
| 04/17/2002 | EP1196156A2 Transnasal anticonvulsive compositions and modulated process |
| 04/17/2002 | EP1196155A1 New use of compounds as antibacterial agents |
| 04/17/2002 | EP1196153A2 Process for the improvement of spermatozoa fertilization activity |
| 04/17/2002 | EP1196152A1 Use of cortisol antagonists in the treatment for heart failure |
| 04/17/2002 | EP1196147A1 Oral liquid compositions |
| 04/17/2002 | EP1196145A1 Methods and apparatus for preparation of lipid vesicles |
| 04/17/2002 | EP1196141A1 Use of at least one extract of a plant of the genus lannea in a cosmetic or dermopharmaceutical composition |
| 04/17/2002 | EP1196138A1 Pre-formed gel sheet |
| 04/17/2002 | EP1196136A1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 04/17/2002 | EP0934290B1 Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same |
| 04/17/2002 | EP0912086A4 Regulation of alzheimer's disease related proteins and uses thereof |
| 04/17/2002 | EP0901378B1 Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophosphoric acid |
| 04/17/2002 | EP0866699B1 The use of cholinesterase inhibitors for the manufacture of a medicament for the treatment of xerostomia |
| 04/17/2002 | EP0837684B1 Pharmaceutical compositions containing a diclofenac salt and thiocolchicoside |
| 04/17/2002 | EP0831911B1 Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure |
| 04/17/2002 | EP0804186B1 Indole diterpene alkaloid compounds |
| 04/17/2002 | EP0742722B1 Method for increasing bioavailability of oral pharmaceutical compositions |
| 04/17/2002 | EP0735890B1 Mixtures of 2',3'-dideoxy-inosine and hydroxycarbamide for inhibiting retroviral spread |
| 04/17/2002 | EP0623146B1 Compositions and methods for inhibiting beta-protein function |
| 04/17/2002 | EP0607278B1 Method for enhancing gut absorption |
| 04/17/2002 | CN1345375A Streptococcus pneumoniae antigens |
| 04/17/2002 | CN1345331A Method and composition for angiogenesis inhibition |
| 04/17/2002 | CN1345314A Amine derivatives as protease inhibitors |
| 04/17/2002 | CN1345246A Compositions and method for prevention or treatment of cancer and bone loss associated with cancer |
| 04/17/2002 | CN1345243A Drugs, foods, drinks and feeds containing cocoa component |
| 04/17/2002 | CN1345242A Method for treatment of leukaemia |
| 04/17/2002 | CN1345239A Heterocyclic containing biphenyl alpha P2 inhibitors and method |
| 04/17/2002 | CN1345238A Method for treatment of neurological or neuropsychiatric disorders |
| 04/17/2002 | CN1345232A Hydrogel particle formulations |
| 04/17/2002 | CN1345224A Composition for cosmetic and dermatological skin care |
| 04/17/2002 | CN1344755A Prep. of degradable polymer, pharmaceutical composition containing the same and its use |
| 04/17/2002 | CN1082822C Cosmetic and skin-useful composition containing water from hot spring or mineral water and agent against acne and oldening |
| 04/16/2002 | US6372957 Transgenic mouse comprising a MEF2 binding site operatively linked to an indicator gene and methods of use |
| 04/16/2002 | US6372919 (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent |
| 04/16/2002 | US6372786 Composition containing sucrafate and a topical anesthetic for humans and animals and method of use thereof |
| 04/16/2002 | US6372784 Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds |
| 04/16/2002 | US6372763 Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI) |
| 04/16/2002 | US6372753 Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
| 04/16/2002 | US6372743 Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines |
| 04/16/2002 | US6372741 Use of CSAID™ compounds as inhibitors of angiogenesis |
| 04/16/2002 | US6372726 Methods of cancer treatment using NAALADase inhibitors |
| 04/16/2002 | US6372724 Modulation of human mast cell activation |
| 04/16/2002 | US6372723 Administering selective adenosine a2a receptor agonist and/or antagonist; occlusion removal; surgery; reroute blood flowthrough bypass graft |